MA44700A - Combinaison d'un anticorps anti-il-10 et d'un oligonucléotide de type cpg-c pour le traitement du cancer - Google Patents

Combinaison d'un anticorps anti-il-10 et d'un oligonucléotide de type cpg-c pour le traitement du cancer

Info

Publication number
MA44700A
MA44700A MA044700A MA44700A MA44700A MA 44700 A MA44700 A MA 44700A MA 044700 A MA044700 A MA 044700A MA 44700 A MA44700 A MA 44700A MA 44700 A MA44700 A MA 44700A
Authority
MA
Morocco
Prior art keywords
cpg
oligonucleotide
antibody
cancer
treatment
Prior art date
Application number
MA044700A
Other languages
English (en)
Inventor
Elliot Keith Chartash
Robert L Coffman
Cristiana Guiducci
Robert S Janssen
Robert A Kastelein
Uyen Truong Phan
Svetlana Sadekova
Ying Yu
Original Assignee
Dynavax Tech Corp
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynavax Tech Corp, Merck Sharp & Dohme filed Critical Dynavax Tech Corp
Publication of MA44700A publication Critical patent/MA44700A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA044700A 2015-05-29 2016-05-26 Combinaison d'un anticorps anti-il-10 et d'un oligonucléotide de type cpg-c pour le traitement du cancer MA44700A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562168470P 2015-05-29 2015-05-29
US201562169321P 2015-06-01 2015-06-01

Publications (1)

Publication Number Publication Date
MA44700A true MA44700A (fr) 2019-02-27

Family

ID=57442233

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044700A MA44700A (fr) 2015-05-29 2016-05-26 Combinaison d'un anticorps anti-il-10 et d'un oligonucléotide de type cpg-c pour le traitement du cancer

Country Status (12)

Country Link
US (1) US20180161427A1 (fr)
EP (1) EP3302554A4 (fr)
JP (1) JP2018516252A (fr)
KR (1) KR20180014010A (fr)
CN (1) CN107949399A (fr)
AU (1) AU2016271023A1 (fr)
BR (1) BR112017025533A2 (fr)
CA (1) CA2986232A1 (fr)
MA (1) MA44700A (fr)
MX (1) MX2017015311A (fr)
RU (1) RU2017145559A (fr)
WO (1) WO2016196178A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158768B2 (en) * 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
US11213593B2 (en) 2014-11-21 2022-01-04 Northwestern University Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
ES2987696T3 (es) * 2015-05-29 2024-11-15 Dynavax Tech Corp Agonista polinucleotídico del receptor de tipo toll 9 para el tratamiento del cáncer de pulmón
BR112017025562A2 (pt) 2015-05-29 2018-08-07 Merck Sharp & Dohme Corp. métodos para tratar câncer em um indivíduo e para tratar um indivíduo humano diagnosticado com câncer
WO2018039629A2 (fr) 2016-08-25 2018-03-01 Northwestern University Acides nucléiques sphériques micellaires obtenus à partir de matrices thermosensibles sans trace
US11433131B2 (en) 2017-05-11 2022-09-06 Northwestern University Adoptive cell therapy using spherical nucleic acids (SNAs)
WO2019234221A1 (fr) 2018-06-08 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de stratification et de traitement d'un patient souffrant de leucémie lymphoïde chronique

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200303759A (en) * 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
ES2381309T3 (es) * 2002-12-23 2012-05-25 Dynavax Technologies Corporation Secuencia de oligonucleótidos inmunoestimuladores y métodos para usar los mismos
PE20050925A1 (es) * 2003-11-10 2005-11-29 Schering Corp Anticuerpo recombinante humanizado anti-interleuquina 10
AU2006211960A1 (en) * 2005-02-08 2006-08-17 Board Of Regents, The University Of Texas System Compositions and methods involving MDA-7 for the treatment of cancer
CA2646626A1 (fr) * 2006-03-22 2007-09-27 Apogenix Gmbh Anticorps specifique de l'il-4 humaine pour le traitement du cancer
JP2009016596A (ja) * 2007-07-05 2009-01-22 Elpida Memory Inc 半導体装置及び半導体装置の製造方法
WO2009022215A1 (fr) * 2007-08-13 2009-02-19 Pfizer Inc. Oligonucléotides immunostimulateurs à motif de combinaison avec activité améliorée

Also Published As

Publication number Publication date
CN107949399A (zh) 2018-04-20
AU2016271023A1 (en) 2017-11-30
BR112017025533A2 (pt) 2018-08-07
CA2986232A1 (fr) 2016-12-08
RU2017145559A (ru) 2019-07-03
MX2017015311A (es) 2018-06-19
JP2018516252A (ja) 2018-06-21
EP3302554A1 (fr) 2018-04-11
US20180161427A1 (en) 2018-06-14
WO2016196178A1 (fr) 2016-12-08
KR20180014010A (ko) 2018-02-07
EP3302554A4 (fr) 2019-02-27

Similar Documents

Publication Publication Date Title
FR25C1001I2 (fr) Compositions d'anticorps pour le traitement de tumeurs
EP3431105A4 (fr) Composition médicinale pour le traitement du cancer
MA55697A (fr) Molécules d'anticorps pour le traitement du cancer
EP3494142A4 (fr) Anticorps anti-siglec-7 pour le traitement du cancer
MA71705A (fr) Substances et procédés pour le traitement d'hémoglobinopathies
MA49144A (fr) Polythérapies pour le traitement du cancer
MA47719A (fr) Esketamine pour le traitement de la dépression
MA44699A (fr) Association d'un antagoniste du pd-1 et d'un oligonucléotide cpg du type c pour le traitement du cancer
EP3436002A4 (fr) Combinaisons pharmaceutiques pour le traitement du cancer
EP3481387A4 (fr) Methodes et compositions pour le traitement de troubles épileptiques
MA42420A (fr) Vaccins pour le traitement et la prévention du cancer
MA44700A (fr) Combinaison d'un anticorps anti-il-10 et d'un oligonucléotide de type cpg-c pour le traitement du cancer
MA50849A (fr) Substances et procédés pour le traitement d'hémoglobinopathies
MA50409A (fr) Polythérapies pour le traitement du cancer
EP3341391A4 (fr) Compositions et procédés pour le traitement de la douleur
MA48637A (fr) Polythérapies pour le traitement du cancer
EP3635130A4 (fr) Médicament de précision pour le traitement et la prévention du risque suicidaire
EP3474854A4 (fr) Associations médicamenteuses pour le traitement du cancer
EP3344325A4 (fr) Administration locale de médicaments pour le traitement de l'asthme
EP3370725A4 (fr) Dosage pédiatrique pour le traitement du cancer avec un inhibiteur d'ezh2
EP3383497A4 (fr) Nouveaux anticorps pour le traitement de cancers
EP3541417A4 (fr) Immunothérapies d'association pour le traitement du cancer
MA43825A (fr) Schémas posologiques pour le traitement d'infections fongiques
EP3397262A4 (fr) Combinaison d'inhibiteur de hdac et d'anticorps anti-pd-l1 pour le traitement de cancer des ovaires
EP3403099A4 (fr) Procédés et compositions pour le traitement du cancer